Osteopontin Is Associated with Multiple Sclerosis Relapses.
IL-6
cytokines
inflammation
multiple sclerosis
osteopontin
relapses
Journal
Biomedicines
ISSN: 2227-9059
Titre abrégé: Biomedicines
Pays: Switzerland
ID NLM: 101691304
Informations de publication
Date de publication:
11 Jan 2023
11 Jan 2023
Historique:
received:
30
11
2022
revised:
23
12
2022
accepted:
05
01
2023
entrez:
21
1
2023
pubmed:
22
1
2023
medline:
22
1
2023
Statut:
epublish
Résumé
Osteopontin, an extracellular matrix protein involved in bone remodeling, tissue repair and inflammation, has previously been associated with increased inflammation and neurodegeneration in multiple sclerosis (MS), promoting a worse disease course. Osteopontin is also likely involved in acute MS relapses. In 47 patients with relapsing-remitting MS, we explored the correlation between the time elapsed between the last clinical relapse and lumbar puncture, and the cerebrospinal fluid (CSF) levels of osteopontin and a group of inflammatory cytokines and adipokines such as resistin, plasminogen activator inhibitor-1, osteoprotegerin, interleukin (IL)-1β, IL-2, IL-6 and IL-1 receptor antagonist (IL-1ra). We also analyzed the correlations between CSF levels of osteopontin and the other CSF molecules considered. Osteopontin CSF concentrations were higher in patients with a shorter time interval between the last clinical relapse and CSF withdrawal. In addition, CSF levels of osteopontin were positively correlated with the proinflammatory cytokines IL-2 and IL-6 and negatively correlated with the anti-inflammatory molecule IL-1ra. Our results further suggest the role of osteopontin in acute MS relapses showing that, in proximity to relapses, osteopontin expression in CSF may be increased along with other proinflammatory mediators and correlated with decreased concentrations of anti-inflammatory molecules.
Sections du résumé
BACKGROUND
BACKGROUND
Osteopontin, an extracellular matrix protein involved in bone remodeling, tissue repair and inflammation, has previously been associated with increased inflammation and neurodegeneration in multiple sclerosis (MS), promoting a worse disease course. Osteopontin is also likely involved in acute MS relapses.
METHODS
METHODS
In 47 patients with relapsing-remitting MS, we explored the correlation between the time elapsed between the last clinical relapse and lumbar puncture, and the cerebrospinal fluid (CSF) levels of osteopontin and a group of inflammatory cytokines and adipokines such as resistin, plasminogen activator inhibitor-1, osteoprotegerin, interleukin (IL)-1β, IL-2, IL-6 and IL-1 receptor antagonist (IL-1ra). We also analyzed the correlations between CSF levels of osteopontin and the other CSF molecules considered.
RESULTS
RESULTS
Osteopontin CSF concentrations were higher in patients with a shorter time interval between the last clinical relapse and CSF withdrawal. In addition, CSF levels of osteopontin were positively correlated with the proinflammatory cytokines IL-2 and IL-6 and negatively correlated with the anti-inflammatory molecule IL-1ra.
CONCLUSIONS
CONCLUSIONS
Our results further suggest the role of osteopontin in acute MS relapses showing that, in proximity to relapses, osteopontin expression in CSF may be increased along with other proinflammatory mediators and correlated with decreased concentrations of anti-inflammatory molecules.
Identifiants
pubmed: 36672686
pii: biomedicines11010178
doi: 10.3390/biomedicines11010178
pmc: PMC9855779
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : Diego Centonze and Georgia Mandolesi RF-2018-12366144
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : Fabio Buttari GR-2018-12366154
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : Progetto Ricerca Corrente to IRCCS Neuromed
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : Progetto Ricerca Corrente to IRCCS San Raffaele; Georgia Mandolesi
Organisme : Fondazione Italiana Sclerosi Multipla (FISM)
ID : Diego Centonze cod. 2019/S/1 and financed or co-financed with the '5 per mille' public funding
Organisme : Fondazione Italiana Sclerosi Multipla (FISM)
ID : Mario Stampanoni Bassi cod. 2020/R-Multi/018 and financed or co-financed with the '5 per mille' public funding
Organisme : funding from CNR to Diego Centonze
ID : Project 'Nuovi Biomarker Diagnostici e Terapeutici delle Malattie Neurodegenerative' - ADOPT co-funded by FOE 2020
Organisme : Fondazione Italiana Sclerosi Multipla (FISM)
ID : Giuseppe Matarese 2018/S/5
Organisme : Progetti di Rilevante Interesse Nazionale (PRIN)
ID : Giuseppe Matarese grant 2017 K55HLC 001
Organisme : Ministero della Salute (Ministry of Health, Italy)
ID : Giuseppe Matarese RF-2019-12371111
Organisme : Fondazione Italiana Sclerosi Multipla (FISM)
ID : FISM
Références
J Neuroimmunol. 1995 Sep;61(2):241-5
pubmed: 7593560
Int J Exp Pathol. 2000 Dec;81(6):373-90
pubmed: 11298186
J Neuroimmunol. 2004 Oct;155(1-2):155-60
pubmed: 15342207
Science. 2001 Nov 23;294(5547):1731-5
pubmed: 11721059
J Neuroimmunol. 2005 Jan;158(1-2):231-9
pubmed: 15589058
Neurology. 1983 Nov;33(11):1444-52
pubmed: 6685237
Int J Mol Sci. 2021 Oct 07;22(19):
pubmed: 34639186
Front Cell Neurosci. 2020 Jun 23;14:120
pubmed: 32655367
Neurol Neuroimmunol Neuroinflamm. 2021 Sep 29;8(6):
pubmed: 34588298
J Clin Invest. 2001 May;107(9):1055-61
pubmed: 11342566
Front Immunol. 2017 Mar 23;8:321
pubmed: 28386258
Ther Adv Neurol Disord. 2022 Jun 21;15:17562864221092124
pubmed: 35755969
Gene Ther. 2007 Jan;14(1):93-8
pubmed: 16929354
J Immunol. 2017 Jun 15;198(12):4553-4560
pubmed: 28583987
J Neuroimmunol. 2003 Jun;139(1-2):150-4
pubmed: 12799033
J Neurol Neurosurg Psychiatry. 1993 Feb;56(2):169-74
pubmed: 8437006
Biomed Res Int. 2017;2017:1879437
pubmed: 28698867
Front Biosci. 2007 Jan 01;12:214-21
pubmed: 17127294
J Neurol. 2018 Nov;265(11):2540-2547
pubmed: 30167879
J Immunol. 2002 Mar 1;168(5):2096-9
pubmed: 11859094
PLoS One. 2022 Jun 27;17(6):e0270607
pubmed: 35759479
Science. 2000 Feb 4;287(5454):860-4
pubmed: 10657301
Mult Scler Relat Disord. 2021 Jun;51:102923
pubmed: 33813096
Curr Alzheimer Res. 2007 Feb;4(1):67-72
pubmed: 17316167
J Neuroimmunol. 1998 May 1;85(1):87-95
pubmed: 9627001
Nat Immunol. 2007 Jan;8(1):74-83
pubmed: 17143274
Ann Neurol. 2003 Jun;53(6):819-22
pubmed: 12783433
J Neuroinflammation. 2014 Feb 18;11:32
pubmed: 24548694
Mult Scler. 2015 Oct;21(11):1443-52
pubmed: 25583841
Mult Scler. 2020 Sep;26(10):1237-1246
pubmed: 31161863
Nat Rev Immunol. 2011 Feb;11(2):85-97
pubmed: 21252989
Arch Neurol. 2008 May;65(5):633-5
pubmed: 18474739
J Immunol. 1987 Sep 1;139(5):1546-9
pubmed: 2957429